MTOR and prostate carcinoma: Given that PI3K/AKT/mTOR pathway and androgen receptor (AR) are highly relevant in the context of prostate cancer, and that there is a crosstalk between the PI3K/AKT/mTOR pathway and the AR axis [8], these findings suggest that extending the use of 3-in-1 drug system [5] to prostate cancer is worth exploring.